Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(133 produits)
- CSF-1R(42 produits)
- EGFR(591 produits)
- Récepteur Ephrin(25 produits)
- FLT(90 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(182 produits)
- SON(3 produits)
- Hck(3 produits)
- IGF-1R(104 produits)
- PDGFR(129 produits)
- PYK2(7 produits)
- Src(82 produits)
- Récepteur TAM(34 produits)
- Tie-2(20 produits)
- Récepteur Trk(57 produits)
- Tyrosine Kinases(24 produits)
- VEGFR(245 produits)
- c-Fms(112 produits)
- c-Kit(116 produits)
- c-Met/HGFR(139 produits)
- c-RET(61 produits)
Affichez 13 plus de sous-catégories
1135 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Andamertinib
CAS :Andamertinib is an EGFR inhibitor with antitumor activity.Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669IGF-1R inhibitor-4
CAS :IGF-1Rinhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound plays a significant role in cancer research.Formule :C13H15ClN4OCouleur et forme :SolidMasse moléculaire :278.737TrkA-IN-8
CAS :TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368TrkC-IN-1
CAS :TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395FMP-API-1
CAS :FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).Formule :C13H14N2O2Couleur et forme :SolidMasse moléculaire :230.262TrkA-IN-9
CAS :TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Formule :C31H32N4O4Couleur et forme :SolidMasse moléculaire :524.61TRK-IN-28
CAS :TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Formule :C27H25F2N7Couleur et forme :SolidMasse moléculaire :485.53Tyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.
Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447EGFR-IN-147
CAS :EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275EGFR ligand-14
CAS :EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formule :C27H19ClFN3OCouleur et forme :SolidMasse moléculaire :455.91Ligritinib
CAS :Ligritinib (AB801) is an orally active inhibitor of the AXL receptor tyrosine kinase. By inhibiting the kinase activity of AXL, Ligritinib blocks its downstream signaling pathways. It is utilized in cancer research, particularly in studies involving non-small cell lung cancer (NSCLC) in combination with chemotherapy.Formule :C33H32N6OCouleur et forme :SolidMasse moléculaire :528.65N-Deshydroxyethyl Dasatinib-C3-NH2
CAS :N-Deshydroxyethyl Dasatinib-C3-NH2 is a target protein ligand-linker conjugate, comprising an LCK ligand and a PROTAC linker, designed to recruit E3 ligase. It is utilized in the synthesis of [PROTACSJ11646].Formule :C23H29ClN8OSCouleur et forme :SolidMasse moléculaire :501.05EGFR-IN-35
CAS :EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96EGFR Ligand-Linker Conjugates 1
CAS :EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formule :C37H47N9O3Couleur et forme :SolidMasse moléculaire :665.83PROTAC Her3-binding moiety 2
CAS :PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formule :C25H25N7O2Couleur et forme :SolidMasse moléculaire :455.51UniPR500
CAS :UniPR500, a derivative of UniPR129, is a competitive antagonist for the EphA2 receptor, with a Ki of 0.78 μM. It reduces the binding of biotinylated Ephrin-A1 to EphA2 in a dose-dependent manner, exhibiting an IC50 value of 1.1 μM.Formule :C36H51N3O4Couleur et forme :SolidMasse moléculaire :589.808EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Couleur et forme :SolidEGFR-IN-23
CAS :EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68Anticancer agent 109
CAS :Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].Formule :C19H15N3O2Couleur et forme :SolidMasse moléculaire :317.34
